Sunpharma Q1 results : Netprofit at Rs1,444 crore
Published On: Friday, July 30, 2021 | By: Team KnowMyStock
Shares of Sun Pharmaceuticals Industries rallied 9 per cent and hit an over four-year high of Rs 767.50 on the BSE in intra-day trade on Friday after the company reported strong results for the June quarter (Q1FY22), The Company reported a consolidated net profit of Rs 1,444 crore for the quarter ended June as against a consolidated net loss of Rs 1,655 crore in the year-ago quarter. Analysts had expected the company to report consolidated net profit of Rs 1,470 crore for the reported quarter. The company reported better-than-expected consolidated sales from operations at Rs 9,669 crore, a growth of 29 per cent over Q1 last year and 14 per cent over Q4 last year. Company reported Rs 7,585.25 crore for the same period a year ago, it added. Analysts had expected 19.5 per cent YoY revenue growth for the quarter. The management said the company witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sale of Covid products.
“We continue to focus on growing our overall business and simultaneously strengthening our global specialty portfolio. The recent in-licensing of Winlevi for the US and Canada is a step forward in this direction,” Dilip Shanghvi, Managing Director of Sun Pharma said.
We are on Telegram!
JOIN our telegram channel to receive updates on Financial News and Stock and FNO Tips.
Click Here!
Follow Us On:
